ALX Oncology Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-160.81	-123.48	-83.46	-50.94	-23.27	-17.4
Depreciation & Amortization	0.84	0.34	0.05	0.2	0.43	0.43
Share-Based Compensation	26.27	23.84	13.91	5.44	0.3	0.27
Other Operating Activities	3.33	10.08	1.4	1.81	4.27	-0.16
Operating Cash Flow	-130.36	-89.22	-68.1	-38.29	-14.25	-13.19
Capital Expenditures	-1.27	-1.43	-0.67	-0.03	-0.35	-0.65
Change in Investments	45.93	-233.99	0	0	0	0
Other Investing Activities	-	-	-4.26	0.64	-	-
Investing Cash Flow	44.66	-235.42	-4.92	0.61	-0.35	-0.65
Share Issuance / Repurchase	59.68	0.9	2.75	368.56	0.01	0
Debt Issued / Paid	-0.39	8.96	-0.28	-6.51	5.92	0
Other Financing Activities	-	-	-	100.83	9.43	-
Financing Cash Flow	59.29	9.86	2.47	462.88	15.36	0
Net Cash Flow	-26.42	-314.78	-70.55	425.2	0.76	-13.84
Free Cash Flow	-131.64	-90.65	-68.77	-38.32	-14.6	-13.84
Free Cash Flow Margin	-	-	-	-3241.96%	-304.46%	-669.71%
Free Cash Flow Per Share	-3.06	-2.23	-1.71	-2.07	-4.75	-5.03

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).